Legislation on information to patients in the EU - will it be worth the effort?
This article was originally published in SRA
Yet more work for the European Medicines Agency and yet more fees levied on the pharmaceutical industry. Those will be sure consequences of the legal framework that is likely to result from the European Commission's newly released amended proposals on the information pharmaceutical companies can provide to patients about their prescription drugs. It is not so clear what the benefits will be to patients.
You may also be interested in...
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.
Bristol Myers Squibb says it is common for cell and gene therapies to revert to the standard timetable as ide-cel follows liso-cel in losing its accelerated assessment status at the European Medicines Agency. Separately, the company has discontinued development of orva-cel, a CAR-T cell therapy that was earlier in the development pipeline.